AstraZeneca

AZN

Market cap $288B

Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug Wainua, expected in the third quarter of 2026. Wainua is a TTR-silencer, a drug that suppresses production of a protein called transthyretin (TTR) which can misfold and accumulate in the heart and nerves, causing a progressive condition known as ATTR-cardiomyopathy (ATTR-CM).

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell (CTC) intelligence company, has signed a master services agreement with AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical group. The deal establishes CelLBxHealth as a qualified service provider to the Anglo-Swedish giant, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples using its Parsortix platform.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval by the Food and Drug Administration (FDA) is based on positive results from the POTOMAC Phase III trial which were presented at the European Society for Medical Oncology (ESMO) Congress 2025 and s.

AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.

AstraZeneca ​said on ‌Wednesday ​the ​U.S. Food ⁠and ​Drug Administration ​has extended ​its ​review deadline for ‌its ⁠experimental breast ​cancer ​pill ⁠camizestrant ​to ​assess ⁠additional data.

Inside a pharmaceutical plant, heat is everywhere—and until recently, almost nobody was paying attention to it.

AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.

AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.

I am initiating AstraZeneca at a "Strong Buy," driven by robust Q1 2026 revenue growth and portfolio momentum. The company's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively. Positive phase 3 data for IMFINZI in unresectable HCC and ULTOMIRIS in IgAN unlock significant expansion opportunities.

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sank.